Treatment News : New Sangamo Genetic Therapy Boosts CD4s, Reduces Reservoir

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » November 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

November 4, 2013

New Sangamo Genetic Therapy Boosts CD4s, Reduces Reservoir

An early study of a genetic therapy has reduced the size of the HIV reservoir in seven out of nine study subjects and has also led to long-term CD4 increases. The biotech company Sangamo BioSciences presented the findings of its Phase I trial of the treatment, called a ZFP Therapeutic, at a conference titled “What Will It Take to Achieve an AIDS-Free World?” in San Francisco.

The open-label trial involved nine people with HIV who, despite ongoing antiretroviral (ARV) therapy and fully suppressed viral loads, did not restore their CD4 levels to 500 or above. Researchers removed immune cells from the participants and genetically engineered them knock out genes that express the CCR5 coreceptor onto which HIV latches in order to infect the cell, thus yielding HIV-resistant CD4s without the coreceptor. Participants received a single infusion of these cells, which constitute a treatment known as SB-728-T. They remained on ARVs throughout.

As a result of the therapy, seven out of nine of the participants experienced a reduction in HIV DNA one year after the infusion, indicating a diminished viral reservoir. The therapy also led to a median long-term increase of 103 CD4 cells among all participants, which was correlated with an increase in the modified CD4 central memory cells—cells which themselves continued to produce HIV-resistant, CCR5-modified CD4 cells.

To read a Sangamo BioSciences release, click here.

Search: Sangamo BioSciences, CD4s, viral reservoir, ZFP Therapeutic, genetic therapy, CCR5, SB-728-T, What Will It Take to Achieve an AIDS-Free World?


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dlw8585
    Fort Lauderdale
    Florida


    romanticseattle
    Tacoma
    Washington


    ernienyc
    Bronx
    New York


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Is HIV/AIDS adequately portrayed in pop culture?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.